Literature DB >> 28477311

Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.

Alfred King-Yin Lam1.   

Abstract

The fourth edition of the World Health Organization (WHO) classification of endocrine tumours contains substantial new findings for the adrenal tumours. The tumours are presented in two chapters labelled as "Tumours of the adrenal cortex" and "Tumours of the adrenal medulla and extra-adrenal paraganglia." Tumours of the adrenal cortex are classified as cortical carcinoma, cortical adenoma, sex cord stromal tumours, adenomatoid tumour, mesenchymal and stromal tumours (myelolipoma and schwannoma), haematological tumours, and secondary tumours. Amongst them, schwannoma and haematological tumours are newly documented. The major updates in adrenal cortical lesions are noted in the genetics of the cortical carcinoma and cortical adenoma based on the data from The Cancer Genome Atlas (TCGA). Also, a system for differentiation of oncocytoma from oncocytic cortical carcinoma is adopted. Tumours of the adrenal medulla and extra-adrenal paraganglia comprise pheochromocytoma, paraganglioma (head and neck paraganglioma and sympathetic paraganglioma), neuroblastic tumours (neuroblastoma, nodular ganglioneuroblastoma, intermixed ganglioneuroblastoma, and ganglioneuroma), composite pheochromocytoma, and composite paraganglioma. In this group, neuroblastic tumours are newly included in the classification. The clinical features, histology, associated pathologies, genetics, and predictive factors of pheochromocytoma and paraganglioma are the main changes introduced in this chapter of WHO classification of endocrine tumours. The term "metastatic pheochromocytoma/paraganglioma" is used to replace "malignant pheochromocytoma/paraganglioma." Also, composite pheochromocytoma and composite paraganglioma are now documented in separate sections instead of one. Overall, the new classification incorporated new data on pathology, clinical behaviour, and genetics of the adrenal tumours that are important for current management of patients with these tumours.

Entities:  

Keywords:  Adrenal; Genetic; Pathology; Tumour; WHO

Mesh:

Year:  2017        PMID: 28477311     DOI: 10.1007/s12022-017-9484-5

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  110 in total

1.  Mature teratomas of the adrenal gland: imaging features.

Authors:  P L Khong; K Y Lam; C G C Ooi; M J Liu; C Metreweli
Journal:  Abdom Imaging       Date:  2002 May-Jun

2.  Composite paraganglioma-ganglioneuroma in the retroperitoneum.

Authors:  Shoji Hirasaki; Hiromitsu Kanzaki; Masato Okuda; Seiyuu Suzuki; Tetsuji Fukuhara; Toshihito Hanaoka
Journal:  World J Surg Oncol       Date:  2009-11-05       Impact factor: 2.754

3.  Silent genetic alterations identified by targeted next-generation sequencing in pheochromocytoma/paraganglioma: A clinicopathological correlations.

Authors:  Suja Pillai; Vinod Gopalan; Chung Y Lo; Victor Liew; Robert A Smith; Alfred King Y Lam
Journal:  Exp Mol Pathol       Date:  2016-12-13       Impact factor: 3.362

4.  The diagnosis and treatment of primary adrenal lipomatous tumours in Chinese patients: A 31-year follow-up study.

Authors:  Juping Zhao; Fukang Sun; Xiaolong Jing; Wenlong Zhou; Xin Huang; Haofei Wang; Yu Zhu; Fei Yuan; Zhoujun Shen
Journal:  Can Urol Assoc J       Date:  2014 Mar-Apr       Impact factor: 1.862

5.  Virilizing Leydig cell adenoma of adrenal gland.

Authors:  W J Pollock; C F McConnell; C Hilton; R L Lavine
Journal:  Am J Surg Pathol       Date:  1986-11       Impact factor: 6.394

Review 6.  The transcriptome that mediates increased cyclic adenosine monophosphate signaling in PRKAR1A defects and other settings.

Authors:  Monalisa F Azevedo; Constantine A Stratakis
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

7.  Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.

Authors:  Noriko Kimura; Ryoichi Takayanagi; Nae Takizawa; Eiji Itagaki; Takayuki Katabami; Narihiko Kakoi; Hiromi Rakugi; Yukihiro Ikeda; Akiyo Tanabe; Takeshi Nigawara; Sadayoshi Ito; Itaru Kimura; Mitsuhide Naruse
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

8.  Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma.

Authors:  Eleonora Duregon; Luca Molinaro; Marco Volante; Laura Ventura; Luisella Righi; Stefania Bolla; Massimo Terzolo; Anna Sapino; Mauro G Papotti
Journal:  Mod Pathol       Date:  2014-01-17       Impact factor: 7.842

9.  Myelolipoma: CT and pathologic features.

Authors:  P J Kenney; B J Wagner; P Rao; C S Heffess
Journal:  Radiology       Date:  1998-07       Impact factor: 11.105

10.  Mediastinal paragangliomas related to SDHx gene mutations.

Authors:  Ilona Michałowska; Jarosław Ćwikła; Aleksander Prejbisz; Paweł Kwiatek; Małgorzata Szperl; Wojciech Michalski; Lucjan Wyrwicz; Mariusz Kuśmierczyk; Andrzej Januszewicz; Anna Maciejczyk; Marta Roszczynko; Mariola Pęczkowska
Journal:  Kardiochir Torakochirurgia Pol       Date:  2016-09-30
View more
  113 in total

Review 1.  Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options.

Authors:  Svenja Nölting; Ashley Grossman; Karel Pacak
Journal:  Exp Clin Endocrinol Diabetes       Date:  2018-09-20       Impact factor: 2.949

2.  Clinical course of adrenal myelolipoma: A long-term longitudinal follow-up study.

Authors:  Oksana Hamidi; Ram Raman; Natalia Lazik; Nicole Iniguez-Ariza; Travis J McKenzie; Melanie L Lyden; Geoffrey B Thompson; Benzon M Dy; William F Young; Irina Bancos
Journal:  Clin Endocrinol (Oxf)       Date:  2020-04-23       Impact factor: 3.478

Review 3.  Adrenal myelolipoma: a comprehensive review.

Authors:  Ábel Decmann; Pál Perge; Miklós Tóth; Peter Igaz
Journal:  Endocrine       Date:  2017-11-21       Impact factor: 3.633

Review 4.  Comprehensive review of evaluation and management of cardiac paragangliomas.

Authors:  Sri Harsha Tella; Abhishek Jha; David Taïeb; Keith A Horvath; Karel Pacak
Journal:  Heart       Date:  2020-05-22       Impact factor: 5.994

5.  HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways.

Authors:  Feifei Xu; Dengqiang Lin; Wen Jiang; Li Meng; Yunze Xu; Chenghe Wang; Xiaojing Wang; Hongchao He; Danfeng Xu; Yu Zhu
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

Review 6.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 7.  Hypertension in Pheochromocytoma and Paraganglioma: Evaluation and Management in Pediatric Patients.

Authors:  Meredith L Seamon; Ikuyo Yamaguchi
Journal:  Curr Hypertens Rep       Date:  2021-05-27       Impact factor: 5.369

8.  HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.

Authors:  Patricia L M Dahia; Roderick Clifton-Bligh; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo; Camilo Jimenez
Journal:  Endocr Relat Cancer       Date:  2020-08       Impact factor: 5.678

9.  Uncommon Metastasizing Site of Adrenocortical Carcinoma.

Authors:  Tarun Kumar; Jitendra S Nigam; Shambhwi Sharma; Madhu Kumari; Jagjit Pandey
Journal:  Cureus       Date:  2021-05-27

Review 10.  Review of the Literature on Leiomyoma and Leiomyosarcoma of the Adrenal Gland: A Systematic Analysis of Case Reports.

Authors:  Maria Sakellariou; Dionysios Dellaportas; Melpomeni Peppa; Dimitrios Schizas; Emmanouil Pikoulis; Konstantinos Nastos
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.